Type 2 Diabetes (T2D) Treatments

Find Type 2 Diabetes (T2D) Treatments

Generic Name

Pioglitazone

Brand Names
OSENI, Alogliptin
FDA approval date: July 15, 1999
Classification: Peroxisome Proliferator Receptor alpha Agonist
Form: Tablet

What is OSENI (Pioglitazone)?

Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. Important Limitations of Use Pioglitazone tablets exert their antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [ see Warnings and Precautions.

Approved To Treat

Top Global Experts

View All
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Who is this study for: Patients with Multiple Sclerosis
Enrollment Status: Recruiting
Publish Date: April 06, 2026
Intervention Type: Drug
Study Drugs: Pioglitazone, Clemastine Fumarate, Hydroxychloroquine, Dantrolene
Study Phase: Phase 1/Phase 2

Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers. They want to see if a change in biomarker levels can predict which drugs a person with MS might respond to.

Randomized, Parallel Group, Dose Escalation Trial of Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus: The PEP-DM Trial
Randomized, Parallel Group, Dose Escalation Trial of Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus: The PEP-DM Trial
Enrollment Status: Recruiting
Publish Date: April 03, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: The purpose of this study is to evaluate efficacy of pioglitazone (PIO) versus empagliflozin (EMPA) to improve glycemic control in people with Chronic Pancreatitis (CP) or Recurrent Acute Pancreatitis (RAP) associated with Diabetes Mellitus (DM). To evaluate mixed meal response in PIO versus EMPA group to better understand physiology of both therapies in CP-DM.

An Open-label, Fixed-sequence, Two-part Study to Assess the Effect of AZD5004 on the Pharmacokinetics of Mitiglinide and Pioglitazone in Healthy Participants
An Open-label, Fixed-sequence, Two-part Study to Assess the Effect of AZD5004 on the Pharmacokinetics of Mitiglinide and Pioglitazone in Healthy Participants
Enrollment Status: Recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Phase: Phase 1

Summary: The purpose of the study is to assess the effect of AZD5004 on the pharmacokinetics (PK) of mitiglinide and pioglitazone in healthy participants.

View All Clinical Trials

Related Latest Advances

Anticancer and apoptotic effect of alogliptin on A549 cancer cell line.
Anticancer and apoptotic effect of alogliptin on A549 cancer cell line.
Journal: Wiadomosci lekarskie (Warsaw, Poland : 1960)
Published: April 09, 2026
Drug repurposing in the management of major depressive disorder: a perspective.
Drug repurposing in the management of major depressive disorder: a perspective.
Journal: East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan
Published: March 31, 2026
Targeted Degradation of Dipeptidyl Peptidase-4 via Proteolysis-Targeting Chimera Technology for Sustained Glycemic Control in Type 2 Diabetes.
Targeted Degradation of Dipeptidyl Peptidase-4 via Proteolysis-Targeting Chimera Technology for Sustained Glycemic Control in Type 2 Diabetes.
Journal: Journal of medicinal chemistry
Published: March 13, 2026
View All Latest Advances

Brand Information